

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Daratumumab in combination with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

No potential equality issues were identified during the scoping process.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Not applicable.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes were made to the draft scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No potential equality issues were identified during the scoping process.

Approved by Associate Director (name): Elisabeth George

Date: 20/12/2017